Glenmark Pharmaceuticals

GPTKB entity

Statements (55)
Predicate Object
gptkbp:instance_of gptkb:pharmaceuticals
gptkbp:acquisition gptkb:N/_A
gptkbp:advertising gptkb:N/_A
gptkbp:awards Various industry awards
gptkbp:ceo Glenn Saldanha
gptkbp:clinical_trial Conducts clinical trials globally
Conducts clinical research in multiple therapeutic areas
gptkbp:collaborations Collaborates with universities
Collaborates with biotech firms
Collaborates with research institutes
gptkbp:conducts_research_on gptkb:N/_A
gptkbp:employees Over 10,000
gptkbp:faction Significant investment in R& D
gptkbp:founded gptkb:1977
gptkbp:founder Glenmark Pharmaceuticals Ltd.
gptkbp:global_presence Strong presence in Asia
Strong presence in Europe
Strong presence in North America
Strong presence in Latin America
gptkbp:head_of_state gptkb:N/_A
gptkbp:headquarters gptkb:Mumbai,_India
https://www.w3.org/2000/01/rdf-schema#label Glenmark Pharmaceuticals
gptkbp:industry Pharmaceuticals
gptkbp:invention Numerous patents filed
gptkbp:market_cap Approximately $2 billion (2021)
gptkbp:market_launch gptkb:Biosimilars
Innovative therapies
New drug launches annually
gptkbp:operates_in Over 80 countries
gptkbp:partnership Academic institutions
Government agencies
Research organizations
Various global pharmaceutical companies
gptkbp:products Branded drugs
Generic drugs
Active pharmaceutical ingredients (APIs)
gptkbp:regulatory_compliance gptkb:N/_A
gptkbp:research_focus gptkb:diabetes
gptkb:Oncology
Respiratory diseases
Chronic diseases
gptkbp:revenue $1.2 billion (2021)
gptkbp:social_responsibility Supports education initiatives
Engages in CSR activities
Supports environmental initiatives
Supports healthcare initiatives
gptkbp:stock_exchange gptkb:BSE
NSE
gptkbp:subsidiary Glenmark Generics Ltd.
gptkbp:sustainability_initiatives Community health programs
Environmental sustainability programs
Employee welfare programs
gptkbp:website www.glenmarkpharma.com
gptkbp:bfsParent gptkb:Zydus_Cadila
gptkbp:bfsLayer 5